Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Filings indexed 195 across all filing types
Latest filing 2025-04-01 Regulatory Filings
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
Annual information form - English.pdf
Regulatory Filings
2025-04-01 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-11-13 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-11-13 English
Interim financial statements/report – English.pdf
Regulatory Filings
2024-11-13 English
Interim MD&A - English.pdf
Regulatory Filings
2024-11-13 English
Interim financial statements/report – English.pdf
Regulatory Filings
2024-08-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.